CDNA — CareDx, Inc.
Is CDNA overbought or oversold? Here is the current MarketMoodz read.
CareDx, Inc. (CDNA) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $74.56. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$74.56
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
See all oversold Healthcare stocks →
AI analysis
CareDx is a specialty diagnostics company centered on transplant monitoring assays that generate recurring lab revenue and offer attractive margin leverage as utilization climbs. The firm benefits from a defensible product set and entrenched relationships with transplant centers, supporting steady revenue visibility and potential margin expansion. Near-term catalysts include broader clinical adoption of noninvasive rejection monitoring, international rollouts, and potential partnership or M&A interest. Key challenges are reimbursement/regulatory pressure, competitive assay entrants, and reliance on transplant volumes and operational execution. Given a measured market tone and sector dynamics favoring specialty care distribution, the path for modest share-price appreciation is supported but contingent on sustaining reimbursement and execution.
Key factors
- Leading position in transplant diagnostics with proprietary donor-derived cell-free DNA and genomic assays that drive recurring, subscription-like lab revenue
- High revenue visibility from durable testing volumes and strong payor relationships/reimbursement for key assays
- Margin expansion potential from leverage in centralized lab operations, higher test mix, and operating efficiencies
- Growth runway from continued adoption of noninvasive rejection monitoring, international expansion and deeper penetration among transplant centers
- Favorable near-term technical environment (measured risk-on session and steady flows into selective growth names) that supports sentiment
- Potential strategic optionality (partnerships/M&A interest from larger diagnostics or medtech players) given specialty niche and recurring revenues
Risks
- Reimbursement pressure or payer audit/clawback risk that could reduce test pricing or slow adoption (heightened regulatory focus in Medicare/MA markets)
- Competition from other molecular/NGS diagnostics providers and new assay entrants that could compress pricing or share
- Volume sensitivity to transplant procedure trends, hospital capital constraints, or shifts in referral patterns
- Operational execution risks including lab scale-up, quality/turnaround maintenance, and supply chain constraints
- Concentration risk if a subset of tests or large customers account for a meaningful portion of revenue
- Macroeconomic or sector rotation that reduces hospital/delivery system budgets or delays procurement and adoption
See today's live rating, score and targets
Members see the live hourly rating for CDNA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.